Abemaciclib mesylate is a CDK inhibitor with selectivity for CDK4 and CDK6. It was approved for the treatment of advanced or metastatic breast cancers.
Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Cancer | CDK
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.
日本语
한국어
Français
Deutsch
España
Türkiye